Actively Recruiting
Evaluation of Etrasimod for Moderately to Severely Active Ulcerative Colitis in Children Aged 2 to Under 12 Years A Phase 2 Open-Label Study
Led by Pfizer · Updated on 2026-10-26
24
Participants Needed
46
Research Sites
205 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, and how the body processes the medicine etrasimod in children aged 2 to under 12 years who have moderate to severe ulcerative colitis. The study is a phase 2, open-label trial focused on treating pediatric participants with this gut disease. The goal is to understand how etrasimod works in this young population and to monitor its effects over time. Participants will take etrasimod by mouth once daily for up to 52 weeks. Those who complete this treatment period may choose to continue in a long-term extension phase lasting up to 4 additional years, totaling up to 5 years of study involvement. This extension allows ongoing assessment of etrasimods safety and effectiveness over a longer period. During the study, participants will be regularly monitored for clinical remission based on the Modified Mayo Score at weeks 12 and 52, along with other clinical responses and endoscopic improvements. Researchers will also track growth measurements, treatment-related side effects, laboratory and vital sign changes, and plasma levels of the drug. Follow-up and safety evaluations continue throughout the treatment and extension periods to ensure comprehensive data collection.
CONDITIONS
Brief Title
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here